Evidence map›Paper›PMID 33389085›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2021

Drug-related problems and risk factors related to unplanned hospital readmission among cancer patients in Belgium.

Majda Koubaity, Anne-Sophie Lechon, Karim Amighi, Marc Van Nuffelen, Michel Moreau, Anne-Pascale Meert, Carine De Vriese

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Majda KoubaityDepartment of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Boulevard du Triomphe, CP 205/07, Access 2, Campus de la Plaine, Building BC, 1050, Brussels, Belgium.ORCID http://orcid.org/0000-0002-5569-6020
Anne-Sophie LechonDepartment of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Boulevard du Triomphe, CP 205/07, Access 2, Campus de la Plaine, Building BC, 1050, Brussels, Belgium.
Karim AmighiDepartment of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Boulevard du Triomphe, CP 205/07, Access 2, Campus de la Plaine, Building BC, 1050, Brussels, Belgium.
Marc Van NuffelenDepartment of Intensive Care and Emergency, Erasme Hospital, Université libre de Bruxelles, Brussels, Belgium.
Michel MoreauDepartment of Information Management Unit (UGI), Institute Jules Bordet, Brussels, Belgium.
Anne-Pascale MeertDepartment of Internal Medicine, Intensive Care Unit and Oncology Emergency, Institute Jules Bordet, Université libre de Bruxelles, Brussels, Belgium.
Carine De VrieseDepartment of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Boulevard du Triomphe, CP 205/07, Access 2, Campus de la Plaine, Building BC, 1050, Brussels, Belgium. cdevries@ulb.ac.be.
Université Libre de Bruxelles · BEInstitut Jules Bordet · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere are about 60,000 diagnoses of cancer per year in Belgium. After hospital care, about 12-13% of cancer patients are readmitted within 30 days after discharge. These readmissions are partly related to drug-related problems (DRP), such as interactions or adverse drug effects (ADE).

objectivesThe aim of this study is to quantify and to classify DRP readmissions within 30 days for cancer patients and to highlight risk factors potentially correlated to readmissions.

methodsThis study is a 6-month observational retrospective study in two care facilities in Brussels: an academic general hospital and an academic oncology center. Patients readmitted within 30 days after their last hospital care for a potential DRP were included. Patient files were evaluated with an intermediate medication review that included interactions analysis (Lexicomp®). The probability of DRP readmission was assessed using the World Health Organization's Uppsala Monitoring Centre (WHO-UMC) system.

resultsThe final population included 299 patients; among them, 123 (41.1%) were readmitted due to DRP (certain DRP (4.9%), probable DRP (49.6%), and possible DRP (45.5%)). Risks factors linked to these DRP were a low Charlson Comorbidity Index, polypharmacy, the kind of hospital, and some chemotherapies (platinum preparations). Among all readmitted patients, the D-type interactions were the most common (44.8%), which suggest a possible therapy modification. However, around 10% of interactions were X-type (drug combination to avoid).

conclusionAlmost 10% of patient readmitted within 30 days were potentially related to a DRP, most of them from adverse drug effects. Four risk factors (low Charlson Comorbidity Index, polypharmacy, the hospital, and some chemotherapies) were highlighted to prevent these readmissions.

Indexed as

AgedAged, 80 and overBelgiumDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleNeoplasmsPatient ReadmissionRetrospective StudiesRisk FactorsBelgiumDrug-related problemsHospitalOncology

Identifiers

PMID33389085
OpenAlexW3119519366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.